Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals: COO Brendan Teehan Terminated Without Cause, Effective Immediately

Neutral Impact 4 of 5 leadership Written later

Acadia Pharmaceuticals said Executive Vice President, Chief Operating Officer and Head of Commercial Brendan Teehan was involuntarily terminated without Cause, effective immediately. Mr. Teehan will stay on as a non-executive employee through December 31, 2024 to help transfer his duties to a successor, and CEO Catherine Owen Adams will assume his responsibilities until one is appointed.

Key points

  • Brendan Teehan's executive role ended effective immediately, per an agreement dated November 18, 2024
  • Teehan remains a non-executive employee until December 31, 2024 to assist with the transition
  • CEO Catherine Owen Adams will assume his responsibilities until a successor is appointed
  • The filing does not name a successor or state the reason for the termination

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECNov 20, 2024, 4:30 PM ET
Accession number0001193125-24-262556

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 20, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.